CHARACTERIZATION OF POULTRY EGG SHELL POWDER AS TABLET MATRIX BASE
DOI:
https://doi.org/10.22159/ijap.2026v18i2.56682Keywords:
Excipients, Processed, Placebo, Drug loaded, CompressibleAbstract
Objective: The present study focused on in-depth characterization of processed poultry egg shell powder (PESP) as a natural tablet diluent and a functional matrix base.
Methods: The eggshells were processed into a fine powder with a high-speed laboratory grinder, sieved through the #60 mesh. Processed PESP was characterized in terms of micromeritics, surface morphology by scanning electron microscopy (SEM), particle size distribution by bi-laser diffraction (BLD), crystallinity by x-ray diffraction (XRD) spectroscopy, functional groups identification by Fourier transform infrared spectroscopy (FTIR), phase changing properties by differential scanning calorimetry (DSC), determination of microbial load and In vitro cytotoxic study by3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) using the human adult low calcium high temperature (HaCaT) keratinocyte cell line on PESP. Prepared tablets, both placebo and drug loaded with PESP as matrix base were studied for tableting properties.
Results: Processed poultry eggshell powder (PESP) exhibited irregular, porous particles with a median size of 208 µm, indicating good flowability and potential for uniform compaction. X-ray diffraction confirmed high crystallinity, while FTIR analysis showed no significant interactions with standard excipients or the model drug, suggesting chemical compatibility. Differential scanning calorimetry revealed phase transitions above 110 °C, indicating thermal stability without significant decomposition. Microbial evaluation demonstrated bacterial and fungal counts within pharmacopeial limits, and in vitro MTT assays on HaCaT keratinocytes showed no detectable cytotoxicity up to 1000 µg/ml. PESP also displayed acceptable compressibility and flow, supporting its suitability as a matrix excipient for tablet formulations. Overall, these findings highlight PESP as a safe, biocompatible, and pharmaceutically promising excipient.
Conclusion: Overall, as a proof -of- concept, preliminary findings demonstrated that PESP possessed functional properties and exhibited optimal tableting properties.
References
1. Aulton ME, Taylor K. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. London: Elsevier; 2018.
2. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
3. Podczeck F. Excipients in the pharmaceutical industry. In: Brittain HG, editor. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 33. Amsterdam: Academic Press; 2007. p. 3–34.
4. Alderborn G. Tablets and compaction. In: Aulton ME, Taylor K, editors. Aulton’s Pharmaceutics. 5th ed. London: Elsevier; 2018. p. 505–40.
5. Kaushal N, Kaur H, Goyal AK. Pharmaceutical excipients and drug allergies: a review. J Pharm Investig. 2021;51:633–47.
6. Dooms M. Interactions and intolerance associated with cellulose derivatives used as excipients. Acta Clin Belg. 2018;73(5):365–9.
7. Patel A, Jacob S, Patil J, Bhargava H. Excipients limitations: challenges in drug formulation and delivery. J Pharm Drug Deliv Res. 2022;11(2):18459.
8. Shirwaikar A, Prabu SL, Kumar GA. Herbal excipients in novel drug delivery systems. Indian J Pharm Sci. 2008;70(4):415–22.
9. Paradkar AR, Mahadik KR, Pawar AP. Natural polysaccharides as pharmaceutical excipients: a review. Drug Dev Ind Pharm. 2021;47(11):1697–710.
10. Nayak AK, Pal D. Natural polysaccharides in drug delivery and biomedical applications. Adv Pharm Bull. 2021;11(2):261–74.
11. Dongyue Y, Hoag SW. The impact of diluents on the compaction, dissolution, and physical stability of amorphous solid dispersion tablets. Int J Pharm. 2024;123924. doi:10.1016/j.ijpharm.2024.123924.
12. Figueiredo A, Silva AM, Lemos MS, Leite-Moreira AF, Moura CS. Risks of dairy-derived excipients in medications for lactose intolerant and cow milk protein allergic patients. Sci Rep.2024;14:15631.
13. Bhatia M, Ahuja G. Hypersensitivity reactions to pharmaceutical excipients: an overview. J Appl Pharm Sci. 2015;5(9):123–31.
14. Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40(1):141–62.
15. Cherukuri R, Singh S, Gaddam S, et al. Intestinal obstruction from excessive intake of microcrystalline cellulose in supplements: a case report. Clin Toxicol (Phila). 2018;56(4):345–8.
16. Patel B, Patel K, Patel H. Orodispersible tablets: excipient functionality and patient acceptability. Int J Pharm Investig. 2019;9(2):47–54.
17. Schreiber R, Klose H, Buxmann H, et al. Case report: severe IgE-mediated hypersensitivity to carboxymethylcellulose with tolerance to crosscarmellose and microcrystalline cellulose.Front Allergy.2025;6:1663395. doi:10.3389/falgy.2025.1663395.
18. Jani GK, Shah DP, Prajapati VD, Jain VC. Gums and mucilages: versatile excipients for pharmaceutical formulations. Asian J Pharm Sci. 2009;4(5):309–23.
19. Salunke S, Tuleu C. The excipient landscape: assessing excipient functionality, safety, and patient acceptability—a pediatric perspective. Int J Pharm.2021;597:120306.
20. Mohamed EM, Hassan MF. Eggshell as a potential pharmaceutical excipient: a review. Int J Pharm Sci Rev Res. 2019;54(2):12–8.
21. Ameh T, Sayyadi R, Ibrahim Y. Evaluation of eggshell powder as a pharmaceutical excipient in tablet formulations. J Pharm Res Int. 2020;32(21):1–11.
22. Boonyuen S, Thumanu K, Srichana T, et al. Utilization of eggshell waste as pharmaceutical excipient: physicochemical and safety studies. Mater Sci Eng C.2020;115:111094.
23. Olorunsola EO, Adikwu MU. The potential of animal-derived excipients in drug formulation: challenges and opportunities. Afr J Pharm Pharmacol. 2013;7(9):451–9.
24. Patel B, Patel K, Patel H, et al. Evaluation of eggshell-derived calcium carbonate as a natural excipient for tablet formulation. Int J Pharm Pharm Sci. 2022;14(4):88–95.
25. United States Pharmacopeia (USP). United States Pharmacopeia and National Formulary USP 46–NF 41. Rockville (MD): United States Pharmacopeial Convention; 2023.
26. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Validation of Analytical Procedures: Q2(R2). Geneva: ICH; 2022.
27. Hickey AJ, Mansour HM. Pharmaceutical Powder and Particles: Fundamentals and Applications. Cham: Springer; 2018.
28. Goldstein JI, Newbury DE, Joy DC, et al. Scanning Electron Microscopy and X-ray Microanalysis. 4th ed. Cham: Springer; 2018.
29. Klug HP, Alexander LE. X-ray Diffraction Procedures. 2nd ed. New York: Wiley; 1974.
30. Höhne G, Hemminger WF, Flammersheim HJ. Differential Scanning Calorimetry. 2nd ed. Cham: Springer; 2003.
31. Stuart B. Infrared Spectroscopy: Fundamentals and Applications. Chichester: Wiley; 2004.
32. Bhattacharjee S. DLS and zeta potential—what they are and what they are not? J Control Release.2016;235:337–51.
33. United States Pharmacopeia (USP). Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests. USP <61>. Rockville (MD): United States Pharmacopeial Convention; 2023.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
35. Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. Boca Raton (FL): CRC Press; 2002.
36. Bolton S, Bon C. Pharmaceutical Statistics: Practical and Clinical Applications. 5th ed. Boca Raton (FL): CRC Press; 2010.
37. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SANJIBAN UTPALKUMAR SARKAR
This work is licensed under a Creative Commons Attribution 4.0 International License.
